Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab

GRELL, Peter, Katarína PETRÁKOVÁ, Marta ŠIMÍČKOVÁ, Marek SVOBODA, Miloslava NEKULOVÁ, Ladislav PECEN, Rostislav VYZULA a Rudolf NENUTIL. Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab. In 19th meeting of European Association For Cancer Research. 1. vyd. Budapešť: European Association for Cancer Research, 2006, s. 207-207.

Základní údaje

• Originální název: Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab
• Název česky: Sérová HER-2/neu: nádorový marker pro monitoring odpovědi na léčbu trastuzumabem u metastatického karcinomu prsu
• Autoři: GRELL, Peter, Katarína PETRÁKOVÁ, Marta ŠIMÍČKOVÁ, Marek SVOBODA, Miloslava NEKULOVÁ, Ladislav PECEN, Rostislav VYZULA a Rudolf NENUTIL.
• Vydání: 1. vyd. Budapešť, 19th meeting of European Association For Cancer Research, od s. 207-207, 1 s. 2006.
• Nakladatel: European Association for Cancer Research

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Stať ve sborníku
• Obor: 30200 3.2 Clinical medicine
• Stát vydavatele: Velká Británie a Severní Irsko
• Utajení: není předmětem státního či obchodního tajemství
• Organizační jednotka: Lékařská fakulta
• Klíčová slova anglicky: serum her2/neu;trastuzumab;breast cancer
• Štítky: breast cancer, serum her2/neu, trastuzumab
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

Introduction: HER-2/neu, the oncoprotein from growth factor receptor family, is overexpressed in primary tumor tissue in approximately 30% patients with breast cancer. Extracellular domain of this oncoprotein is released into the circulation and by recent studies it has prognostic and predictive signification similar to HER-2/neu in tissue. Material and Methods: We evaluated dynamics of serum HER-2/neu (S_HER2) changes during the course of trastuzumab-based therapy, by the specific antibody directed against the extracellular domain (ELISA, Oncogene Science, USA). We had opportunity to repeatedly tested S_HER2 in 69 patients with metastatic breast cancer undergoing treatment in years 200-2005 in our institute. Results: Patients without the response to treatment at the time of the first restaging (3 months), had significantly elevated S_HER2 levels, that generally do not drop below the discriminatory level. The patients with the best clinical response achieved (complete or partial response) are commonly S_HER2 negative after 3 months of the therapy, even if they were serum-positive at the beginning of the treatment. Serum CA15-3 and CEA levels do not show significant differences in this two groups of responders. Likewise in longitudinally monitoring over the time course of trastuzumab-based treatment the predictor of the therapy failure is mainly elevated S_HER2. Conclusion: Monitoring the concentrations of serum HER2 during the trastuzumab therapy appears to be a suitable therapy efficacy validation parameter both at the start and during long-term therapy application. Acknowledgements: The work was supported by grants from IGA MZCR: No. NR/8335-3 and No. NR/8270-3.

Anotace česky

Introduction: HER-2/neu, the oncoprotein from growth factor receptor family, is overexpressed in primary tumor tissue in approximately 30% patients with breast cancer. Extracellular domain of this oncoprotein is released into the circulation and by recent studies it has prognostic and predictive signification similar to HER-2/neu in tissue. Material and Methods: We evaluated dynamics of serum HER-2/neu (S_HER2) changes during the course of trastuzumab-based therapy, by the specific antibody directed against the extracellular domain (ELISA, Oncogene Science, USA). We had opportunity to repeatedly tested S_HER2 in 69 patients with metastatic breast cancer undergoing treatment in years 200-2005 in our institute. Results: Patients without the response to treatment at the time of the first restaging (3 months), had significantly elevated S_HER2 levels, that generally do not drop below the discriminatory level. The patients with the best clinical response achieved (complete or partial response) are commonly S_HER2 negative after 3 months of the therapy, even if they were serum-positive at the beginning of the treatment. Serum CA15-3 and CEA levels do not show significant differences in this two groups of responders. Likewise in longitudinally monitoring over the time course of trastuzumab-based treatment the predictor of the therapy failure is mainly elevated S_HER2. Conclusion: Monitoring the concentrations of serum HER2 during the trastuzumab therapy appears to be a suitable therapy efficacy validation parameter both at the start and during long-term therapy application. Acknowledgements: The work was supported by grants from IGA MZCR: No. NR/8335-3 and No. NR/8270-3.

Návaznosti

• NR8335, projekt VaV: Název: Predikce chemosenzitivity / chemorezistence na cílenou protinádorovou terapii u pacientek s karcinomem prsu s prokázanou HER-2 pozitivitou, na podkladě analýzy Akt signální dráhy a sérové hladiny HER-2 receptoru